Nové poznatky o patogenezi folikulárního lymfomu a koncepty cílené léčby
| Title in English | Novel Findings in Follicular Lymphoma Pathogenesis and the Concepts of Targeted Therapy |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Klinická onkologie |
| MU Faculty or unit | |
| Citation | |
| web | https://www.linkos.cz/english-summary/klinicka-onkologie-journal/2017-08-15-4-en/novel-findings-in-follicular-lymphoma-pathogenesis-and-the-concepts-of-targeted/ |
| Doi | http://dx.doi.org/10.14735/amko2017247 |
| Field | Oncology and hematology |
| Keywords | Follicular Lymphoma |
| Description | The molecular pathogenesis of follicular lymphoma (FL) was partially revealed by the discovery of BCL2 translocations to the region encoding the immunoglobulin heavy chain, which accompany the vast majority of cases. This aberration leads to the ectopic and constitutive expression of anti-apoptotic BCL2 protein in B-cells. Nevertheless, the aberration alone is not sufficient for FL development, which suggests necessity of further genetic aberrations acquisition for neoplastic transformation to FL. Their discovery has been enabled by recent progress in the field of massive parallel sequencing (next generation sequencing), which revealed high number of genetic aberrations connected with onset and progression of FL. The occurrence of many of these aberrations in the early stages of the disease, and the fact that they are shared by the majority of patients with FL, fundamentally changed our former understanding of the disease onset. Furthermore, in a large fraction of patients, FL undergoes histological transformation to a more aggressive lymphoma, which is also associated with specific genetic alterations. In this review, we summarize the current knowledge of molecular pathways connected with FL biology and discuss their role in the context of normal B-cell development. Understanding of FL biology is essential for the development of new targeted therapies and the stratification of patients, and potentially also for the selection of treatment for specific patients who share the same genetic aberrations. |
| Related projects: |